title: Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer.
abstract: OBJECTIVE
  The objective of this study was to evaluate the response rate and survival of patients with locally advanced uterine cervical cancer who were treated with intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC).
  
  
  METHODS
  Twenty-three untreated patients with stages IIIa-IVa cervical cancer were enrolled in the study. PPPEC was administered twice at 2 weeks interval using high-dose cisplatin alone (140-250 mg/m(2)) or high-dose cisplatin plus mitomycin C (7 mg/m(2)), pepleomycin (7 mg/m(2)) and 5-fluorouracil (700 mg/m(2)). Eighteen patients in whom the tumor downstaging was confirmed underwent radical surgery following PPPEC, whereas in the remaining five patients, radiotherapy was administered.
  
  
  RESULTS
  Two weeks after the second PPPEC, the median volumetric tumor reduction and tumor response were 76% and 87%, respectively. Histologic response was 96%, while the tumor downstaging reached 83%. The curative surgery rate achieved was 89%. Five-year progression-free survival was 47% and 5-year survival rate was 74%.
  
  
  CONCLUSIONS
  High-dose intraarterial infusion chemotherapy under PPPEC effectively achieved tumor downstaging and resulted in the favorable performance of the subsequent radical surgery and improved the 5-year survival rate of patients with locally advanced uterine cervical cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. mosa@med.kobe-u.ac.jp
authors.forename: Satoru
authors.initials: S
authors.lastname: Motoyama
authors.forename: Shinya
authors.initials: S
authors.lastname: Hamana
authors.forename: Yonson
authors.initials: Y
authors.lastname: Ku
authors.forename: Jovelle B
authors.initials: JB
authors.lastname: Laoag-Fernandez
authors.forename: Masashi
authors.initials: M
authors.lastname: Deguchi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Yoshida
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tominaga
authors.forename: Takeshi
authors.initials: T
authors.lastname: Iwasaki
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Ohara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Maruo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D017663:Peplomycin / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery
chemical_list: D016685:Mitomycin; D017663:Peplomycin; D002945:Cisplatin; D005472:Fluorouracil